Half of all women with HIV are diagnosed late in Europe
Many women in the WHO European Region, particularly those in their 40s, are diagnosed at a late stage of HIV infection when their immune system is already starting to fail. They are three to four times more likely to be diagnosed late than younger women. According to data for 2018 released today by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, women accounted for one-third of the 141 000 new HIV diagnoses in the Region, indicating that this population needs more attention in Europe's prevention and testing efforts.
Know your status: get tested during European Testing Week
On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
It is always time to test: Spring European Testing Week
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
The benefits of HIV treatment: undetectable means you do not pass on the virus
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
Because it’s best to know: start of European HIV-Hepatitis testing week
An estimated 122 000 people living with HIV across Europe are not aware of their HIV infection and a large number out of the estimated 9 million Europeans that are affected by chronic hepatitis B or C have not yet been tested or diagnosed. ECDC welcomes the efforts of European HIV-Hepatitis Testing Week which starts today.
ECDC study: nearly one in six new HIV diagnoses in Europe are among people over 50
A study published in The Lancet HIV today showed that while the rate of newly reported HIV cases in Europe remained steady in younger people between 2004 and 2015, it increased by 2% each year overall in older people. With around 30 000 newly diagnosed HIV infections reported each year over the last decade, the HIV epidemic remains a significant public health problem in the 31 countries of the European Union and European Economic Area (EU/EEA),
The continuum of HIV care: how is Europe doing?
The continuum of HIV care is a framework that enables countries to monitor the effectiveness of their HIV response - from diagnosis towards viral suppression (which means that the virus is no longer detectable in the blood). This report provides a snapshot of the status of the continuum of care for the whole region as well as each of the 48 countries reporting at least some continuum data.